

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1. (Currently amended) A method of inhibiting the proliferation of vascular smooth muscle cells in a subject in need thereof, which subject (a) has had a heart attack, (b) has had a coronary bypass, (c) has been diagnosed with decreased circulation to the heart, (d) has undergone angioplasty, (e) has an endovascular stent, (f) has a hemodialysis graft, or (g) has a vascular graft, said method comprising administering an inhibitor of a soluble epoxide hydrolase to said subject.

2. (Currently amended) A method of claim 1, wherein said inhibitor of a soluble epoxide hydrolase is a derivative of a pharmacophore selected from the group consisting of urea, carbamate, or amide.

3. (Original) A method of claim 2, wherein said pharmacophore is covalently bound to an adamantane and to a 12 carbon chain dodecane.

4. (Original) A method of claim 2, wherein said inhibitor is a derivative of urea.

5. (Original) A method of claim 4, wherein said derivative of urea is selected from the group consisting of an isomer of adamantyl dodecyl urea, N-cyclohexyl-N'-dodecyl urea (CDU) and N, N'-dicyclohexylurea (DCU).

6. (Withdrawn) A method of claim 1 wherein said inhibitor of a soluble epoxide hydrolase is selected from the group consisting of a lipid alkoxide, a lipophilic diimide, a phenyl glycidol, and a chalcone oxide.

7. (Withdrawn) A method of claim 6, wherein said inhibitor is a lipid alkoxide.
8. (Withdrawn) A method of claim 6, wherein said lipophilic diimide is dicyclohexylcarbodiimide.
9. (Withdrawn) A method of claim 6, wherein said phenyl glycidol is S, S-4-nitrophenylglycidol.
10. (Withdrawn) A method of claim 6, wherein said chalcone oxide is selected from the group consisting of 4-phenylchalcone oxide and 4-fluourochalcone oxide.
11. (Original) A method of claim 1, wherein the subject in need thereof is a patient who has had a heart attack.
12. (Original) A method of claim 11, wherein the subject in need thereof has had a coronary bypass.
13. (Original) A method of claim 1, wherein the subject in need thereof has undergone angioplasty.
14. (Original) A method of claim 1, wherein the subject in need thereof has a stent in an arterial lumen.
15. (Currently amended) A method of claim 14, in which said stent comprises a material comprising an inhibitor of a soluble ~~expoxide~~ epoxide hydrolase.
16. (Currently amended) A method of claim 15, wherein said material comprising an inhibitor of a soluble ~~expoxide~~ epoxide hydrolase releases said inhibitor into its surroundings over time.

17. (Currently amended) A method of claim 14, wherein said material comprising an inhibitor of a soluble ~~expoxide~~ epoxide hydrolase further comprises *cis*-epoxyeicosatrienoic acids (EETs).

18. (Original) A method of claim 1, wherein the subject in need thereof has a hemodialysis graft.

19. (Currently amended) A method of claim 18, in which said graft comprises a material comprising an inhibitor of a soluble ~~expoxide~~ epoxide hydrolase.

20. (Currently amended) A method of claim 19, wherein said material comprising an inhibitor of a soluble ~~expoxide~~ epoxide hydrolase releases said inhibitor into its surroundings over time.

21. (Currently amended) A method of claim 19, wherein said material comprising an inhibitor of a soluble ~~expoxide~~ epoxide hydrolase further comprises *cis*-epoxyeicosatrienoic acids (EETs).

22. (Original) A method of claim 1, wherein said subject in need thereof has had a natural or synthetic vessel engrafted to enhance blood flow around an area.

23. (Currently amended) A method of claim 22, wherein said subject has a synthetic vessel engrafted, which synthetic vessel comprises a material comprising an inhibitor of a soluble ~~expoxide~~ epoxide hydrolase.

24. (Currently amended) A method of claim 23, wherein said material comprising an inhibitor of a soluble ~~expoxide~~ epoxide hydrolase releases said inhibitor into its surroundings over time.

25. (Currently amended) A method of claim 23, wherein said material comprising an inhibitor of a soluble ~~expoxide~~ epoxide hydrolase further comprises *cis*-epoxyeicosatrienoic acids (EETs).

26. (New) A method of inhibiting proliferation of vascular smooth muscle cells in a subject in need thereof, said method comprising administering an inhibitor of soluble epoxide hydrolase and a *cis*-epoxyeicosatrienoic acid (EET) to said subject.

27. (New) A method of inhibiting proliferation of cells with inappropriate cell cycle regulation, said method comprising administering an inhibitor of soluble epoxide hydrolase.